Current Essential Testing in Early Breast Cancer

Current Essential Testing in Early Breast Cancer

Wednesday, March 1, 2023
Webinar -- 7:00 PM ET
https://www.clinicaloptions.com/EBCTestingJoin1

Agenda

Welcome and Program Overview

Role of BRCA Testing and Adjuvant Olaparib in Early Breast Cancer

  • Identifying which patients to test for BRCA
  • Discussion of the OlympiA trial

Practical Points With Initiating Olaparib

  • Dosing and administration, supportive medications
  • Adverse event monitoring and management

Clinical Implementation of Adjuvant Olaparib

  • Concurrent therapies and sequencing
  • Discussion of patient cases

Final Thoughts and Audience Question and Answer Session

Faculty

Faculty
Allison Butts, PharmD, BCOP

Clinical Coordinator, Oncology Pharmacy
Director, PGY2 Oncology Residency Program
UK HealthCare
Lexington, Kentucky

Faculty
Charles E. Geyer, Jr., MD

Professor of Medicine
Division of Hematology/Medical Oncology
Department of Internal Medicine
University of Pittsburgh UPMC Hillman Cancer Center
Staff Attending
Breast Medical Oncology
UPMC Magee Women's Hospital
Pittsburgh, Pennsylvania

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new biomarker testing and therapies into individualized treatment plans for early-stage breast cancer.

Target Audience
This program is intended for medical oncologists, pharmacists, NP/PAs, nurses, genetic counselors, pathologists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Develop genetic testing strategies that incorporate best communication techniques and expert guidance for all patient subgroups with EBC that may benefit from PARP inhibition
  • Identify patients who should be tested for BRCA mutations and communicate to colleagues and patients the rationale and steps for corrective action for those not tested
  • Communicate to colleagues and patients the improvement in overall survival gained by adding PARP inhibition to the adjuvant treatment of patients with germline BRCA mutations
  • Integrate PARP inhibition into treatment plans and sequence strategies for patients that may also be appropriate for other newly approved treatments for EBC
  • Manage treatment-related adverse events in the early-stage breast cancer setting associated with new treatment options to improve adherence, improve patient experience and optimize outcomes

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ProCE, LLC. Clinical Care
Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-23-020-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) and ProCE, LLC require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and ProCE policy. CCO and ProCE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.